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the growth of newly formed hybridomas. 15 ,39-41
The work performed on this aspect in the 1980s
has cu1minated with the discovery that a charac-
terized plasmacytoma/hybridoma growth fac-
tor42,43 was identical to interleukin-6 (IL-6), which
is a pleiotropic cytokine active on the differentia-
tion of B lymphocytes.44 The importance of adding
exogenous IL-6 (or medium conditioned by IL-6-
producing cells such as the P388D1 monocytic
cells) to hybridoma cultures was further shown by
the observation that IL-6 preferentialIy promoted
the survival of the hybridomas secreting MoAbs.45
The dependence to IL-6 is rapidly lost during pro-
longed cultures.
Another important aspect of the culture of newly
formed hybridomas is the quality of the fetal calf
serum used. The quality parameters are not yet
defined, but it is elear that certain serum lots are
much better than others for promoting the growth
of newly formed B celI hybridomas. The relative
performance of the serum lots should be tested in a
fusion experiment rather than by their effect on the
growth of myeloma ar established hybridoma
cells. 45
Source of Antigen-Activated B Lymphocytes
lt is quite elear that the activation of antigen-
specific B lymphocytes is a parameter that is much
more important than the immortalization step. As a
matter of fact, myeloma cells fUse efficiently only
with activated B lymphocytes that are at a differ-
entiation stage somewhere between resting B lym-
phocytes and fully differentiated plasma cells. 46
Preparation of B lymphocytes at the appropriate
differentiation stage is relatively easy in the murine
system but represents a major problem in human
hybridoma technology.
Murine Lymphocytes
The routine protocol for preparing murine B
lymphocytes suitable for efficient fusion is to im-
munize a group of mice with the antigen of inter-
est, determine the serum antibody level in the in-
dividual animals, select the animaI showing the
highest antigen-specific response, and recover the
activated spleen cells 3 or 4 days after a last injec-
tion ("boost") of antigen. 15 This basic protocol
has been used since the original description of the
hybridoma technology and has been successful
thousands of times. However, it is not unerring,
and all investigators in this field have experienced
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failures most probably caused by the absence of
antigen-activated lymphoblasts in the spleen cells
recovered on the fusion day. Many of these fail-
ures may be caused by the induction in the animal
immune system of a suppression/tolerance state
preventing the final activation step. The possible
reasons for this phenomenon are diverse and may
include such parameters as seasonal variations
(springtime is not very good) and the pampering of
animals. One measurable parameter that may
cause this phenomenon is the immunization proto-
col; we have observed that hyperimmunization of
mice was not advisable for the preparation of a
high number of antihuman red blood cells Mo-
Abs.47 Another parameter that is relevant to trans-
fusion medicine concems the optimal time period
between the final antigen boost and the fusion ex-
periment. We have previously shown that the op-
timal period may be shorter (2 instead of 3 to 4
days) for some antigens such as the blood group A
antigen.48
Although several factors influencing the yield of
antigen-activated B cells are still not well defined,
it is elear that most problems can probably be
avoided by using groups of mice and vańous im-
munization schedules.
Human Lymphocytes
The lack of a suitable and reproducible source of
antigen-activated human B lymphocytes has been
and still is the major difficulty in the preparation of
human MoAbs by the hybridoma technology. The
reasons for this are multiple. Obviously, humans
cannot be immunized with antigens of interest.
Furthermore, the peripheral blood was unti! re-
cently (discussed subsequentIy) the only routinely
available source of human B cells (at least to blood
banks).
In vitro immunization and activation. In the
1980s, much effect was made in the development
of conditions favoring the in vitro immunization
and activation of human peripheral blood lympho-
cytes (PBL). Such systems have been de-
scribed49 ,50 and human MoAbs have been prepared
from the B cells activated in vitro. 51-54 However, it
is generally recognized that the efficiency of such
systems is low compared with murine in vivo sys-
tems. In transfusion medicine-related work, sev-
erallaboratories (mostly in Europe) have been suc-
cessful in the preparation of human anti-Rh
antibodies by using in vitro-activated (pokeweed
